Details
Related items

ACT-2

No description specified

LHA ID: 86X1JGJUMP-2

Projects: GLA - German Lymphoma Alliance

Investigation position:

Help

Tree Split Graph

Export PNG

Click below to download a copy of the image

Download

Creators and Submitter

Creators

Marita Ziepert
René Hänsel

Submitter

René Hänsel

Activity

Views: 1538

Created: 4th May 2021 at 15:12

Last updated: 4th May 2021 at 15:12

Related items

Projects (1)
Studies (1)
Resources (2)
Publications (1)
Data files (5)
People (2)
Programmes (1)

GLA - German Lymphoma Alliance

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study ...

Programme: NHL

Public web page: https://www.dshnhl.org

Organisms: Homo sapiens

Human Diseases: non-Hodgkin lymphoma, B-cell lymphoma

ACT-2

GLA - German Lymphoma Alliance

All creators

Marita Ziepert

René Hänsel

Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)

Submitter: René Hänsel

Investigation: ACT-2

Resources: ACT-2 trial data, ACT-2 trial metadata

Study type: Not specified

Snapshots: No snapshots

Created: 4th May 2021 at 15:13, Last updated: 4th Jun 2021 at 09:12

ACT-2 trial metadata

GLA - German Lymphoma Alliance

All creators

René Hänsel

No description specified

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: ACT-2

Study: ACT-2

Human Diseases: No human diseases

Data files: ACT-2 trial data Metadata, ACT-2 trial data odm-Metadata

Snapshots: No snapshots

Created: 2nd Jun 2021 at 12:20, Last updated: 4th Jun 2021 at 09:11

ACT-2 trial data

GLA - German Lymphoma Alliance

All creators

René Hänsel

No description specified

Submitter: René Hänsel

Resource type: Experimental Assay Type

Technology type: Technology Type

Investigation: ACT-2

Study: ACT-2

Human Diseases: No human diseases

Data files: ACT-2 trail data CSV, ACT-2 trial data ODM, ACT-2 trial data SPSS

Snapshots: No snapshots

Created: 2nd Jun 2021 at 12:19, Last updated: 2nd Jun 2021 at 12:28

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

GLA - German Lymphoma Alliance

All authors

Markus Löffler

Marita Ziepert

Abstract (Expand)

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61-80 in an open-label, randomized phase 3 trial. … Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade >/=3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%-39%], 28% [15%-40%], and 37% ([23%-50%] for A-CHOP, and 24% [12%-35%], 29% [17%-41%], and 56% [44%-69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5-1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5-1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9-2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Authors: G. G. Wulf, B. Altmann, M. Ziepert, F. D'Amore, G. Held, R. Greil, O. Tournilhac, T. Relander, A. Viardot, M. Wilhelm, C. Wilhelm, A. Pezzutto, J. M. Zijlstra, E. V. D. Neste, P. J. Lugtenburg, J. K. Doorduijn, M. V. Gelder, G. W. van Imhoff, F. Zettl, F. Braulke, M. Nickelsen, B. Glass, A. Rosenwald, P. Gaulard, M. Loeffler, M. Pfreundschuh, N. Schmitz, L. Trumper